Syndax Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Syndax Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Syndax Pharmaceuticals Inc recorded a cumulative net loss of $-221 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -39.12%.

However, within the Healthcare sector 477 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3870, from total ROA ranking in the first quarter of 2026 at 4584.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	18 %	-26.23 %	-37.26 %	29.42 %	17.74 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-221	-243	-285	-312	-335
Return On Assets (TTM)	-39.12 %	-45.26 %	-49.26 %	-47.34 %	-53.44 %
SNDX's Total Ranking	# 3870	# 4584	# 4014	# 4140	# 4247
Total Assets (TTM) in million	704	473	530	551	596
Seq. Total Assets Change	48.87 %	-10.77 %	-3.88 %	-7.58 %	-6.93 %
Seq. Net Income Change	-	-	-	-	-

SNDX's 5 Years Annual ROA >> Back to SNDX Management Effectiveness >> Compare SNDX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 189
Sector	# 478
Overall	# 3741

Return On Assets Statistics
High	Average	Low
8.09 %	-45.7 %	-73.26 %
(Dec 31 2021)		(Mar 31 2020)

Financial Statements
Syndax Pharmaceuticals Inc 's Assets	$ 704 million	SNDX's Balance sheet
Syndax Pharmaceuticals Inc 's Income	$ -49 million	Quarterly SNDX's Income Statement
SNDX's Income by Division		See SNDX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-37.26 %	37.8 %	23.21 %	10.83 %	49.25 %
Total Assets in million	530	844	613	497	449
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-285	-319	-209	-149	25
Annual Return On Assets	-53.88 %	-37.75 %	-34.17 %	-30.03 %	5.56 %

SNDX's 5 Years Annual ROA >> Back to SNDX Management Effectiveness >> Compare SNDX ROA to its Competitors

More Return On Assets Ratios
SNDX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SNDX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SNDX's Competitors
Subscribers only: Roa for Syndax Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for SNDX's Customers

You may also want to know
SNDX's Roi	SNDX's Inventory Turnover Ratio	SNDX's Growth Rates	SNDX's Dividend Comparisons
	SNDX's Profitability Ratios	SNDX's Asset Turnover Ratio	SNDX's Dividend Growth
SNDX's Roe	SNDX's Valuation Ratios	SNDX's Financial Strength Ratios	SNDX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:27:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.